Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A recombinant porcine-like uricase used as a drug to treat severe gout.

Etymologies

Sorry, no etymologies found.

Examples

  • Researchers at Duke University Medical Center and Savient Pharmaceuticals have recently conducted a phase II trial of a drug called pegloticase which shows great promise in reducing the level of uric acid in the blood to targets levels within a few hours.

    MyLinkVault Newest Links

  • Because it changed the application for its gout treatment pegloticase, Savient said the U.S.

    Options Traders Circle Drug Firms

  • Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA(TM) (pegloticase), which was approved by the FDA on

    Savient Pharmaceuticals Provides Business Update - Yahoo! Finance

  • Indianapolis, Indiana have commenced regularly scheduled commercial manufacturing campaigns to build inventory of pegloticase and KRYSTEXXA.

    Savient Pharmaceuticals Provides Business Update - Yahoo! Finance

  • Company, has continued to manufacture pegloticase and has recently manufactured two batches of pegloticase which have met all specifications.

    Savient Pharmaceuticals Provides Business Update - Yahoo! Finance

  • Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ pegloticase for the treatment of chronic gout in adult patients refractory to conventional therapy.

    Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer - Yahoo! Finance

  • Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA (TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy.

    FinanzNachrichten.de: Aktuelle Nachrichten

  • The decrease was primarily due to $2.0 million in lower manufacturing related expenses including $4.3 million of decreased technology transfer costs from our proposed secondary source supplier of pegloticase API as the majority of the work was completed in the prior year.

    The Earth Times Online Newspaper

  • Completed the manufacture of three consecutive batches of pegloticase active pharmaceutical ingredient (API) drug substance at our third party contract manufacturer (CMO), in our effort to revert to the manufacturing process used to manufacture pegloticase API drug substance from our pivotal KRYSTEXXA?

    The Earth Times Online Newspaper

  • The decrease was primarily due to $3.9 million in lower manufacturing related expenses including $2.2 million of lower technology transfer costs from our proposed secondary source supplier of pegloticase API as the majority of the work was completed in the prior year or postponed until 2010, and $2.5 million of raw material purchases during the same period in 2008.

    The Earth Times Online Newspaper

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.